Brokerages expect Calithera Biosciences Inc (NASDAQ:CALA) to announce earnings per share (EPS) of ($0.49) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have made estimates for Calithera Biosciences’ earnings. The lowest EPS estimate is ($0.50) and the highest is ($0.48). Calithera Biosciences posted earnings of ($0.52) per share in the same quarter last year, which suggests a positive year over year growth rate of 5.8%. The business is expected to issue its next quarterly earnings report on Wednesday, November 6th.
According to Zacks, analysts expect that Calithera Biosciences will report full-year earnings of ($1.89) per share for the current year, with EPS estimates ranging from ($2.23) to ($1.54). For the next fiscal year, analysts forecast that the firm will post earnings of ($1.63) per share, with EPS estimates ranging from ($2.01) to ($1.25). Zacks’ earnings per share calculations are a mean average based on a survey of sell-side analysts that cover Calithera Biosciences.
Calithera Biosciences (NASDAQ:CALA) last posted its quarterly earnings data on Thursday, August 8th. The biotechnology company reported ($0.58) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.55) by ($0.03).
Several equities research analysts have commented on CALA shares. ValuEngine lowered shares of Calithera Biosciences from a “buy” rating to a “hold” rating in a research note on Wednesday, September 4th. Zacks Investment Research lowered shares of Calithera Biosciences from a “buy” rating to a “hold” rating in a research note on Wednesday, October 9th. Finally, Citigroup set a $8.00 price target on shares of Calithera Biosciences and gave the stock a “hold” rating in a research note on Friday, August 9th.
NASDAQ:CALA opened at $2.72 on Friday. The firm has a market cap of $146.80 million, a price-to-earnings ratio of -1.83 and a beta of 1.83. Calithera Biosciences has a 52 week low of $2.45 and a 52 week high of $6.90. The firm has a 50-day moving average price of $3.34 and a two-hundred day moving average price of $4.56.
Several hedge funds have recently modified their holdings of CALA. SG Americas Securities LLC purchased a new stake in shares of Calithera Biosciences during the 2nd quarter worth approximately $112,000. Wells Fargo & Company MN boosted its holdings in Calithera Biosciences by 32.6% in the 2nd quarter. Wells Fargo & Company MN now owns 94,890 shares of the biotechnology company’s stock worth $370,000 after buying an additional 23,354 shares during the period. Connor Clark & Lunn Investment Management Ltd. bought a new position in Calithera Biosciences in the 2nd quarter worth approximately $63,000. Monashee Investment Management LLC bought a new position in Calithera Biosciences in the 2nd quarter worth approximately $1,170,000. Finally, Acadian Asset Management LLC boosted its holdings in Calithera Biosciences by 42.2% in the 2nd quarter. Acadian Asset Management LLC now owns 81,239 shares of the biotechnology company’s stock worth $317,000 after buying an additional 24,125 shares during the period. Institutional investors own 63.86% of the company’s stock.
Calithera Biosciences Company Profile
Calithera Biosciences, Inc, a clinical-stage bio-pharmaceutical company, focuses on the discovery and development of small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. Its lead product candidate is CB-839, an inhibitor of glutaminase, which is in Phase II clinical trial to treat solid tumors.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Calithera Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calithera Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.